Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study

Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study

Introduction. Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can also severely impact their quality of life. About half of the patients receiving this type of oncologic treatment will develop cutaneous react...

Full description

Bibliographic Details
Main Authors:	Barbu Maria Alexandra, Niţipir Cornelia, Voiosu Theodor, Giurcăneanu Călin
Format:	Article
Language:	English
Published:	Sciendo 2018-06-01
Series:	Romanian Journal of Internal Medicine
Subjects:	exanthema toxicity egfr tyrosine kinase inhibitor quality of life chemotherapy
Online Access:	https://doi.org/10.2478/rjim-2018-0002

Similar Items

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective
by: Dennis Niebel, et al.
Published: (2021-08-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
by: K. K. Laktionov, et al.
Published: (2019-06-01)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
by: Lingzhi Hong, et al.
Published: (2022-07-01)

Skin microbial dysbiosis is a characteristic of systemic drug-related intertriginous and flexural exanthema-like lesions induced by EGFR inhibitor
by: Wenqi Liu, et al.
Published: (2023-11-01)

Adverse cutaneous effects of neratinib
by: Ramiz N. Hamid, et al.
Published: (2019-07-01)

Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients
by: Gerber Peter, et al.
Published: (2012-02-01)

Cutaneous Adverse Drug reactions: A Four-Year Study from Western Nepal
by: S Neupane, et al.
Published: (2018-08-01)

Clinicopathological Characteristics and Real-life Data of Patients Receiving Tyrosine Kinase Inhibitor in Metastatic EGFR Mutant Non-small Cell Lung Carcinoma
by: Barış EKİNCİ, et al.
Published: (2023-12-01)

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
by: Leydis Luna Torres, et al.
Published: (2021-10-01)

In silico and in vitro evaluation of novel carbothioamide-based and heterocyclic derivatives of 4-(tert-butyl)-3-methoxybenzoic acid as EGFR tyrosine kinase allosteric site inhibitors
by: Imad M. Al-Rubaye, et al.
Published: (2024-01-01)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
by: Francesco Bellinato, et al.
Published: (2021-11-01)

Rash: the only one clinical manifestation of dengue
by: Sarah María Regueira Betancourt, et al.
Published: (2015-12-01)

Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents
by: Rania S.M. Ismail, et al.
Published: (2016-06-01)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
by: Vito Longo, et al.
Published: (2021-07-01)

DRESS syndrome – A dermatological emergency – Sulfasalazine-related acute drug reaction case report
by: Krzysztof Kanabaj, et al.
Published: (2023-09-01)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
by: Tadashi Nishimura, et al.
Published: (2021-04-01)

Tyrosine Kinase Receptors in Oncology
by: Jorge Esteban-Villarrubia, et al.
Published: (2020-11-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Epidemiologic Characteristics of Patients Admitted to Emergency Department with Dermatological Complaints; a Retrospective Cross sectional Study
by: Deniz Kilic, et al.
Published: (2019-08-01)

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
by: Nichole E. M. Kaufman, et al.
Published: (2021-02-01)

Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors
by: Zwitter Matjaz, et al.
Published: (2017-07-01)

A Five-Year Review of Adverse Cutaneous Drug Reaction in a Tertiary Care Hospital in Yogyakarta, Indonesia
by: Dyah Ayu Mira Oktarina, et al.
Published: (2021-11-01)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
by: Kate S, et al.
Published: (2019-01-01)

Redox-dependent regulation of epidermal growth factor receptor signaling
by: David E. Heppner, et al.
Published: (2016-08-01)

The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer
by: Oana-Stefana Purcaru, et al.
Published: (2021-05-01)

Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma
by: Milena Casula, et al.
Published: (2023-03-01)

Oxygen Tension Regulates Lysosomal Activation and Receptor Tyrosine Kinase Degradation
by: Jaewoo Hong, et al.
Published: (2019-10-01)

mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy
by: Yan Zheng, et al.
Published: (2017-10-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
by: Noorwati SUTANDYO, et al.
Published: (2019-09-01)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
by: Keunchil Park, MD, PhD, et al.
Published: (2021-09-01)

How to manage drug-virus interplay underlying skin eruptions in children
by: Francesca Mori, MD, PhD, et al.
Published: (2024-03-01)

Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
by: Chia-Yu Chu, et al.
Published: (2017-06-01)

Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Daisy Wai-Ka Chan, et al.
Published: (2022-04-01)

Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
by: Maria Kowalska, et al.
Published: (2016-05-01)

RON is not a prognostic marker for resectable pancreatic cancer
by: Tactacan Carole M, et al.
Published: (2012-09-01)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
by: Chieh-Lung Chen, et al.
Published: (2023-09-01)

ПРИОБРЕТЕННАЯ РЕЗИСТЕНТНОСТЬ К ИНГИБИТОРАМ ТИРОЗИНКИНАЗЫ EGFR: ПУТИ ПРЕОДОЛЕНИЯ
Published: (2017-11-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)